Skip to main content

Table 1 Patient and tumor characteristics

From: Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors

  Total Percentage
Number of patient samples
 Total 801 100
Age
 Mean ± SD 62.25 ± 13.7  
 Median (range) 63 (22–90)
Tumor size
 <2 cm 400 49.9
 ≥2–5 cm 358 44.7
 >5 cm 43 5.4
Histology
 Ductal 638 79.7
 Lobular 118 14.7
 Other 45 5.6
Tumor stage
 T1 413 51.6
 T2 342 42.7
 T3 38 4.7
 T4 8 1
Grade
 I 91 11.4
 II 502 62.7
 III 208 26
Nodal status
 N0 492 61.4
 N1 226 28.2
 N2 51 6.4
 N3 32 4
Menopausal status
 Premenopausal 167 20.8
 Perimenopausal 51 6.4
 Postmenopausal 583 72.8
Receptor status
 ER+ 681 85
 ER- 120 15
 PgR+ 563 70.3
 PgR- 238 29.7
 HER2+ 110 13.7
 HER2- 691 86.3
 HR+ 688 85.9
 HR- 113 14.1
Receptor-defined subtype
 Luminal A-like 510 63.7
 Luminal B-like (HER2 positive) 74 9.2
 Luminal B-like (HER2 negative) 104 13
 HER2 positive (non-luminal-like) 36 4.5
 TNBC 77 9.6
  1. ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2, TNBC triple negative breast cancer